Taysha Gene Therapies Inc (TSHA) - Net Assets
Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) has net assets worth $211.94 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($300.35 Million) and total liabilities ($88.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TSHA intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $211.94 Million |
| % of Total Assets | 70.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | 158.89% |
| 10-Year Change | N/A |
| Growth Volatility | 3112.92 |
Taysha Gene Therapies Inc - Net Assets Trend (2019–2025)
This chart illustrates how Taysha Gene Therapies Inc's net assets have evolved over time, based on quarterly financial data. Explore how efficiently does Taysha Gene Therapies Inc generate cash to assess how effectively this company generates cash.
Annual Net Assets for Taysha Gene Therapies Inc (2019–2025)
The table below shows the annual net assets of Taysha Gene Therapies Inc from 2019 to 2025. For live valuation and market cap data, see market cap of Taysha Gene Therapies Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $246.94 Million | +245.25% |
| 2024-12-31 | $71.53 Million | -4.55% |
| 2023-12-31 | $74.94 Million | +7796.42% |
| 2022-12-31 | $949.00K | -99.01% |
| 2021-12-31 | $95.38 Million | -62.04% |
| 2020-12-31 | $251.30 Million | +186249.63% |
| 2019-12-31 | $-135.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Taysha Gene Therapies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71018500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $-192.00K | -0.08% |
| Other Components | $958.43 Million | 388.12% |
| Total Equity | $246.94 Million | 100.00% |
Taysha Gene Therapies Inc Competitors by Market Cap
The table below lists competitors of Taysha Gene Therapies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Evergreen New Material Technology Inc. Co. A
SHG:603125
|
$1.68 Billion |
|
PC Connection Inc
NASDAQ:CNXN
|
$1.68 Billion |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
$1.68 Billion |
|
Medicover AB (publ)
ST:MCOV-B
|
$1.68 Billion |
|
RAPT Therapeutics Inc
NASDAQ:RAPT
|
$1.68 Billion |
|
Greatech Technology Bhd
KLSE:0208
|
$1.68 Billion |
|
Okeanis Eco Tankers Corp.
NYSE:ECO
|
$1.68 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
$1.68 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taysha Gene Therapies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 71,525,000 to 246,938,000, a change of 175,413,000 (245.2%).
- Net loss of 108,995,000 reduced equity.
- New share issuances of 264,306,000 increased equity.
- Other comprehensive income increased equity by 3,839,000.
- Other factors increased equity by 16,263,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-109.00 Million | -44.14% |
| Share Issuances | $264.31 Million | +107.03% |
| Other Comprehensive Income | $3.84 Million | +1.55% |
| Other Changes | $16.26 Million | +6.59% |
| Total Change | $- | 245.25% |
Book Value vs Market Value Analysis
This analysis compares Taysha Gene Therapies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $5.85 | x |
| 2020-12-31 | $14.23 | $5.85 | x |
| 2021-12-31 | $2.53 | $5.85 | x |
| 2022-12-31 | $0.02 | $5.85 | x |
| 2023-12-31 | $0.65 | $5.85 | x |
| 2024-12-31 | $0.29 | $5.85 | x |
| 2025-12-31 | $0.77 | $5.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Taysha Gene Therapies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1115.27%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.39x
- Recent ROE (-44.14%) is above the historical average (-2573.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.10 Million |
| 2020 | -17.11% | 0.00% | 0.00x | 1.03x | $-68.13 Million |
| 2021 | -182.97% | 0.00% | 0.00x | 2.24x | $-184.06 Million |
| 2022 | -17493.57% | -6635.25% | 0.02x | 133.06x | $-166.11 Million |
| 2023 | -148.88% | -722.06% | 0.09x | 2.31x | $-119.06 Million |
| 2024 | -124.85% | -1071.62% | 0.05x | 2.24x | $-96.45 Million |
| 2025 | -44.14% | -1115.27% | 0.03x | 1.39x | $-133.69 Million |
Industry Comparison
This section compares Taysha Gene Therapies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taysha Gene Therapies Inc (TSHA) | $211.94 Million | 0.00% | 0.42x | $1.68 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 … Read more